SIGLEC-8 and CD117 Antibody Libraries for Balanced Mast Cell Targeting

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing therapeutic antibodies for SIGLEC and CD117 targeting mast cells and eosinophils are not balanced in immunological effects with efficacy, and there is a need for compositions and methods for generating antibodies for SIGLEC and CD117.

Innovation Solution

Development of antibodies and antibody fragments with high specificity and affinity for SIGLEC-8 and CD117, including monoclonal, polyclonal, bi-specific, and multispecific antibody fragments, to treat diseases such as asthma, allergies, and cancer.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If existing therapeutic antibodies are used to target mast cells and eosinophils, then some therapeutic effect is achieved, but the immunological effects are not balanced with efficacy

Engineering Contradiction:

Improvebalance between immunological effects and efficacyVSAvoidunbalanced immunological effects

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent employs bispecific and multispecific antibodies that segment the immune response by simultaneously targeting multiple antigens (SIGLEC-8 and CD117) with distinct antibody arms. This segmentation allows independent optimization of each antigen binding while achieving balanced immunological effects through coordinated action against multiple mast cell and eosinophil markers.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent develops universal antibody platforms that can target multiple antigens (SIGLEC-8, CD117, and other mast cell/eosinophil markers) with a single therapeutic composition. This multi-functionality enables a single antibody preparation to address multiple disease mechanisms simultaneously, achieving balanced immunological effects across different pathological processes.

Inventive Principle:

Principle #6Universality (Multi-functionality)

2Reliability

If antibodies are designed to bind with high specificity and affinity to SIGLEC-8 and CD117, then therapeutic efficacy is improved, but the design process becomes more challenging

Engineering Contradiction:

Improvebinding specificity and affinityVSAvoidantibody design complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent employs computational algorithms and in silico modeling to perform preliminary antibody design and optimization before actual synthesis. Virtual screening and predictive algorithms pre-identify promising antibody candidates with high specificity and affinity for SIGLEC-8 and CD117, reducing the complexity of the physical design process by establishing theoretical frameworks in advance.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent uses computational algorithms and bioinformatics tools as intermediaries between the design goal (high specificity/affinity) and the actual antibody synthesis. These intermediary computational models simulate and predict antibody-antigen interactions, serving as a bridge that simplifies the complex design process by providing theoretical guidance before experimental work.

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS20260001953A1Variant nucleic acid libraries for mast cells

Publication Date: 2026.01.01 TWIST BIOSCIENCE CORP

AI summary

Provided herein are antibodies and antibody fragments relating to SIGLEC-8 and CD117. Provided herein are methods and compositions relating to SIGLEC-8 and/or CD117 libraries having nucleic acids encoding for a scaffold comprising a SIGLEC-8 and/or CD117 domain. SIGLEC-8 and/or CD117 libraries described herein encode for immunoglobulins such as antibodies.